Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Inclusion criteria :

• Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) ≥7%.
• Estimated glomerular filtration rate (eGFR) ≥25 and ≤60 milliliter/minute (mL/min)/1.73 square meter (m^2).
• Age 18 years or older with at least one major cardiovascular risk factor or age 55years or older with at least two minor cardiovascular risk factors.
• Signed written informed consent.

Exclusion criteria:

• Antihyperglycemic treatment has not been stable within 12 weeks prior to screening.
• Planned coronary procedure or surgery after randomization.
• Lower extremity complications (such as skin ulcer, infection, osteomyelitis, andgangrene) identified during screening and requiring treatment at randomization.
• Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during thestudy. The above information is not intended to contain all considerations relevant to aparticipant's potential participation in a clinical trial.